935,450 Shares in COMPASS Pathways PLC Sponsored ADR $CMPS Bought by Eagle Health Investments LP

Eagle Health Investments LP acquired a new position in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 935,450 shares of the company’s stock, valued at approximately $5,360,000. COMPASS Pathways accounts for 1.4% of Eagle Health Investments LP’s holdings, making the stock its 18th biggest position.

A number of other institutional investors also recently bought and sold shares of the stock. GSA Capital Partners LLP purchased a new position in COMPASS Pathways during the 3rd quarter valued at about $389,000. AdvisorShares Investments LLC boosted its holdings in COMPASS Pathways by 33.9% in the third quarter. AdvisorShares Investments LLC now owns 232,345 shares of the company’s stock worth $1,331,000 after purchasing an additional 58,804 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in shares of COMPASS Pathways by 141.6% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 57,597 shares of the company’s stock worth $330,000 after buying an additional 33,755 shares during the last quarter. Flagship Harbor Advisors LLC grew its stake in shares of COMPASS Pathways by 64.6% during the 3rd quarter. Flagship Harbor Advisors LLC now owns 46,361 shares of the company’s stock valued at $266,000 after purchasing an additional 18,190 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its position in COMPASS Pathways by 26.1% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 276,991 shares of the company’s stock worth $1,587,000 after acquiring an additional 57,340 shares during the period. 46.19% of the stock is owned by institutional investors.

COMPASS Pathways News Summary

Here are the key news stories impacting COMPASS Pathways this week:

• Positive Sentiment: COMP360 met the primary endpoint in a late‑stage (Phase 3) study, driving optimism about regulatory and commercial prospects for the psilocybin therapy. This is the main catalyst for the rally. Compass Pathways’ depression treatment meets main goal in late‑stage study
• Positive Sentiment: Compass announced it will report new clinical data from two ongoing Phase 3 trials (COMP005 and COMP006) and provided a timeline for additional Phase 3 results, reinforcing near‑term news flow that supports further upside. Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
• Positive Sentiment: Market activity shows heightened bullish positioning: unusually large call option volume (over 10,000 calls) and extremely heavy equity volume suggest speculative and institutional buying around the trial news, which amplified the stock move. (Internal trading/activity reports)
• Neutral Sentiment: Public and media coverage (Investing.com, PharmaLetter, MSN) amplified investor attention; press coverage supports momentum but doesn’t guarantee regulatory approval or commercial success. Compass Pathways stock soars after positive Phase 3 trial results
• Neutral Sentiment: Reported short‑interest data in the filings appears erroneous (0 shares / NaN changes) and is unreliable as an indicator of bearish positioning or squeeze potential at present.
• Neutral Sentiment: Third‑party analyst commentary and forecasts (e.g., Lifesci Capital coverage) exist but are secondary to the actual trial readouts for near‑term price action. What is Lifesci Capital’s Forecast for CMPS FY2025 Earnings?
• Negative Sentiment: Compass launched a proposed $150M public offering of ADSs (and pre‑funded warrants), which can dilute existing shareholders and may cap near‑term upside despite the positive data. Investors should weigh dilution risk against trial progress. Compass Pathways Launches Proposed $150.0 Million Public Offering

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Morgan Stanley raised their target price on shares of COMPASS Pathways from $10.00 to $11.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of COMPASS Pathways in a research note on Wednesday, January 21st. Lifesci Capital raised shares of COMPASS Pathways to a “strong-buy” rating in a report on Thursday, February 12th. Compass Point set a $15.00 price objective on COMPASS Pathways in a research report on Thursday, February 12th. Finally, Royal Bank Of Canada increased their target price on COMPASS Pathways from $16.00 to $21.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.11.

COMPASS Pathways Stock Up 31.3%

Shares of NASDAQ CMPS opened at $7.63 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23. The firm has a 50-day simple moving average of $6.77 and a two-hundred day simple moving average of $5.89. COMPASS Pathways PLC Sponsored ADR has a 1 year low of $2.25 and a 1 year high of $8.80. The company has a market cap of $732.63 million, a P/E ratio of -2.81 and a beta of 1.92.

COMPASS Pathways Company Profile

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.